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Recently, we reported the combination of multitargeted ErbB1 inhibitor–DNA damage combi-molecules with OCT in order to
downregulate ErbB1 and activate SSTRs. Absence of translation to cell kill was believed to be partially due to insuﬃcient ErbB1
blockage and DNA damage. In this study, we evaluated cell response to molecules that damage DNA more aggressively and
induce stronger attenuation of ErbB1 phosphorylation. We used three cell lines expressing low levels (U87MG) or transfected
to overexpress wildtype (U87/EGFR) or a variant (U87/EGFRvIII) of ErbB1. The results showed that Iressa±HN2 and the combi-
molecules, ZRBA4 and ZR2003, signiﬁcantly blocked ErbB1 phosphorylation in U87MG cells. Addition of OCT signiﬁcantly
altered cell cycle distribution. Analysis of the DNA damage response pathway revealed strong upregulation of p53 by HN2 and
the combi-molecules. Apoptosis was only induced by a 48h exposure to HN2. All other treatments resulted in cell necrosis.
This is in agreement with Akt-Bad pathway activation and survivin upregulation. Despite strong DNA damaging properties and
downregulationofErbB1phosphorylationbythesemolecules,thestrongesteﬀectofSSTRactivationwasoncellcycledistribution.
Therefore, any enhanced antiproliferative eﬀects of combining ErbB1 inhibition with SSTR activation must be addressed in the
context of cell cycle arrest.
1.Background
The genetic heterogeneity of solid tumours presents a chal-
lenge to cancer therapy such that single-targeted approaches,
whether with nonselective cytotoxic drugs or highly speciﬁc
kinase inhibitors, often fail due to the development of drug
resistance. Invariably, as one receptor or pathway is blocked,
alternate pathways substitute for the drug target. Moreover,
if the target is not completely blocked, downstream compo-
nents may be able to compensate. Therefore, modern chem-
otherapeutic strategies must adopt a more divergent target-
ingapproach.Chemogenomicstrategiesseektoidentifymol-
ecules which can target, upon minor modiﬁcation, multiple
membersofthesamefamilyofproteins(e.g.,proteinkinases,
GPCRs, or nuclear hormone receptors) [1, 2]. However, this
remains a strategy whereby similar receptors with potentially
similar functions within a tumour are targeted. The optimal
strategy for an eﬃcient multitargeting approach should be
divergent to avoid the adverse eﬀects of target redundancy
at the advanced states of tumour progression. Over the past
few years, we have designed molecules capable of targeting
structurally unrelated cellular components (i.e., receptors
and DNA). The fact that our unimolecular drugs that
target both ErbB1 and DNA can be 10–20 times more
potent than the combination of their single-target counter-
parts conﬁrms the eﬃciency of divergent targeting [3–7].
Within the same context, we and others recently reported
interactions between SSTRs (GPCRs) and ErbBs (RTKs)
suggestingthatthesetworeceptorfamiliesmightbeidealtar-
gets for our divergent strategy (Scheme 1)[ 8–10]. Therefore,2 Journal of Signal Transduction
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Scheme 1: Principle of divergent targeting.
we recently designed a divergent targeting strategy whereby
we activated somatotstatin (SST) receptors (SSTRs) with
octreotide (OCT), blocked epidermal growth factor (EGF)
receptor (ErbB1/EGFR) with kinase inhibitors, and ErbB1-
DNA targeting combi-molecules and induced DNA damage.
SST functions as a potent inhibitor of hormone and
growth factor secretion as well as a modulator of cell prolif-
eration through its cognate receptors SSTR1–5 and regulates
a variety of signal transduction pathways including the
mitogen-activated protein kinase (MAPK) pathway [11–16].
In contrast to SSTRs, ErbBs play fundamental roles in devel-
opment, proliferation, diﬀerentiation, survival, and trans-
formation [17–19]. Major ErbB1 downstream signalling
pathways include Ras/Raf/MEK/MAPK, PI3K/Akt, STAT,
and PLCγ [18, 20, 21]. While both SSTRs and ErbBs activate
theMAPKpathway,SST-inducedMAPKactivationresultsin
delayed cell cycle progression and EGF activation promotes
proliferation. Therefore, SSTR and ErbB1 are true divergent
targets.
In a recent study, we showed exacerbation of cell cycle
perturbations following the combination of multitargeted
ErbB1-DNA combi-molecules with OCT, a SSTR agonist
[22].Thelackoftranslationintocellkillwasbelievedtobein
part due to insuﬃcient ErbB1 inhibition and DNA damage.
Here, we report the analysis of cell response following expo-
sure to concurrent treatment of OCT with combinations
of single-target molecules and unimolecular multitargeted
combi-molecules that damage DNA more aggressively and
induce stronger attenuation of ErbB1 phosphorylation.
In this study, we combined strong ErbB1 TKIs with more
potent chloroethylating DNA damaging drugs and investi-
gated the cell signalling response to divergent targeting that
induced concomitant ErbB1 inhibition, DNA damage, and
SSTR activation. To this end, we analyzed the modulation of
key proteins in the SSTR, MAPK, ErbB1-related signalling,
and DNA damage response pathway (Scheme 2)a sw e l la s
cell cycle distributions with the purpose of identifying a
pharmacological eﬀect (see point of convergence, Scheme 1)
that is signiﬁcantly enhanced by the divergent targeting
process.
2. Methods
2.1. Materials. EGF was obtained from Roche Diagnostics
(Indianapolis, IN). Mouse monoclonal antibodies against
p21 (sc-817) and rabbit polyclonal antibodies against ErbB1
(sc-03), GADD45 (sc-797) and phosphotyrosine (sc-7020),
were from Santa Cruz (Santa Cruz, CA). Rabbit polyclonal
antibodies against phospho- and total Erk 1/2 (9101, 9102),
phospho- and total p38 (9211, 9212), phospho- and total
JNK (9251, 9252), phospho- and total p53 (9284, 2527),
phospho-andtotalAkt(4060,9272),andphospho-andtotal
Bad (9291, 9295, 9292) were purchased from Cell Signalling
Technology (Mississauga, ON). Rabbit polyclonal antibodies
against survivin (AF886) were obtained from R&D Systems
(Minneapolis, MN). Mouse monoclonal antibodies against
XRCC1 (MS-434) and ERCC1 (MS-647) were purchased
from LabVision (Fremont, CA). Ciproﬂoxacin and mouse
monoclonalantibodiesagainstα-actinin(A-5044)werefrom
Sigma. Horseradish peroxidase-conjugated goat anti-rabbit
and goat anti-mouse secondary antibodies (IgG) were from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Cell culture media, Amphotericin B, HEPES, L-glutamine,
and gentamycin sulfate were purchased from Wisent (St.
Bruno, QC), while G418 was obtained from EMD Chemicals
(Gibbstown, NJ). All other reagents were of analytical grade
and purchased from various local suppliers.
2.2. Drug Treatment. ZRBA4 and ZR2003 were synthe-
sized in our laboratory according to previously published
procedures [23, 24]. Iressa (geﬁtinib) was provided byJournal of Signal Transduction 3
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Scheme 2: Key signalling pathways targeted with our divergent targeting strategy. The multitargeted approach includes activating SSTRs,
inhibiting ErbB1, and inducing DNA damage. Key proteins analysed in this study are circled, while pathways not investigated are represented
by dotted lines.
AstraZeneca,whilemechlorethamine(HN2)wasfromSigma
and OCT was purchased from Bachem (Torrance, CA). The
structures of these ﬁve drugs are presented in Figure 1.I n
all assays, drugs were resuspended in dimethyl sulfoxide
(DMSO) and subsequently diluted in serum-supplemented
medium immediately prior to use, unless otherwise speci-
ﬁed. DMSO concentration never exceeded 0.2% (v/v).
We combined Iressa and HN2 at equimolar concentra-
tions to maintain the same ratio of ErbB1 TKI: DNA damage
molecules as the combi-molecules.
2.3. Cell Lines and Culture. U87MG glioma cells (Ameri-
can Type Culture Collection, Manassas, VA) and isogenic
U87/EGFR and U87/EGFRvIII glioma cells (generous gifts
from Dr. Frank Furnari, University of California, La Jolla,
CA)weremaintainedinDMEMmediumsupplementedwith
10%FBS,L-glutamine(1.76μM),HEPES(5.25mg/mL),and
antibiotics (26.8μM ciproﬂoxacin, 0.04mg/mL gentamycin
sulfate, 0.11μg/mL Amphotericin B) at 37◦Ci na na t m o -
sphere of 5% CO2/95% air. Selection pressure on the two
transfected cell lines was maintained by supplementing the
culture media with 400μg/mL G418. All experiments were
performedoncellsbetweenpassage2and4.Inallassays,cells
were plated in DMEM without G418 24h prior to treatment
of subconﬂuent monolayers.
2.4. Alamar Blue Assay. Inhibition of cell proliferation was
monitored with CellTiter Blue (Promega) as per the man-
ufacturer’s instructions. Brieﬂy, cells were plated in 96-well
plates and allowed to attach overnight. Cells were exposed
to individual or combination treatments for six days. Treat-
ments were terminated by the addition of 60μLC e l l T i t e r
Blue (1:4 dilution in PBS). Plates were incubated at
37◦C for an additional 2.5h, while viable cells metabolized
resazurin (maximum absorbance of 605nm) into resoruﬁn,
a ﬂuorescent metabolite (maximum absorbance of 573nm).
This translated into a ﬂuorometric colour change that was
captured using SOFTmax Pro 4.3LS (Molecular Devices,
Sunnyvale, CA) connected to a SpectraMAX Gemini plate
reader (Molecular Devices, Sunnyvale, CA). The following
ﬁlters were used: 580nm for excitation and 600nm for
ﬂuorescence emission. Data were analysed using GraphPad
Prism4(GraphPadSoftwareInc,SanDiego,CA).IC50 values
were calculated from three independent experiments run in
triplicate. Statistical analysis was carried out using a one-way
ANOVA, followed by a post hoc Tukey’s test. P values < 0.05
were considered statistically signiﬁcant.
2.5. Cell Cycle Analysis. Flow cytometric analysis of cell cycle
proﬁles was performed on nonsynchronized cell populations
as previously described with minor adjustments [25, 26].
Brieﬂy, cells were plated in 6-well plates, allowed to grow
until 65–75% conﬂuency in serum-supplemented medium,
and subsequently exposed to serial dilutions of drugs, alone
or in combination, for 24 or 48h at 37◦C. Treatments were
terminatedbyaspiratingthemediaandrinsingthewellswith
PBS. Cells were subsequently collected by trypsinization,
centrifuged (3500rpm for 5min) and washed twice with4 Journal of Signal Transduction
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Figure 1: Chemical structures of Iressa, mechlorethamine (HN2), binary ErbB1-DNA damage combi-molecules (ZRBA4 and ZR2003), and
octreotide (OCT).
PBS. Cells were ﬁxed by slowly adding 1mL ethanol (70%)
with continuous vortexing and then stored at 4◦Cf o r
up to eight days. The day of analysis, cells were pelleted
by centrifugation (3500rpm for 5min), rinsed twice with
PBS and incubated with 200μL freshly prepared propidium
iodide (PI)/RNAse solution (50μg/mL, 100μg/mL, resp.) in
the dark for 30min at 37◦C. Data were collected using a
BD FACSCalibur (BD Biosciences, Mississauga, ON) and
the percentage of cells in each phase was calculated using
FlowJo 8.4.6 (Tree Star, Ashland, OR). Data represent two
independent experiments run in duplicate. Unpaired two-
tailed t-test were used to identify signiﬁcant changes in cell
cycledistributionsupontheadditionofOCT.P values<0.05
were considered statistically signiﬁcant.Journal of Signal Transduction 5
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Figure 2: Dose-dependent inhibition of EGF-induced ErbB1 activation in U87MG, (a) U87/EGFR (b), and U87/EGFRvIII (c) glioma cells.
Serum-starved cells were treated with the indicated concentrations of Iressa ± mechlorethamine (HN2), ZRBA4, or ZR2003 for 2h followed
bya20minEGF(50ng/mL)stimulation.Celllysates(40μg)werefractionatedbySDS-PAGEandprobedwithantiphosphotyrosine(1:1000)
antibodies (see Materials and Methods for details). Blots were subsequently stripped and reprobed for total ErbB1 (1:1000) followed by α-
actinin (1:1500). Major protein bands of 170 (ErbB1) and 100 kDa (α-actinin) were obtained.
2.6. Apoptosis. Cell kill was determined by Annexin V-FITC
binding as previously described with minor modiﬁcations
[27]. Brieﬂy, cells were plated in 6-well plates and allowed to
attachovernight.Cells(65–75%conﬂuent)weretreatedwith
a range of drug dilutions prepared in serum-supplemented
m e d i u mf o r2 4o r4 8ha t3 7 ◦C. Treatments were terminated
by rinsing the wells with PBS, and cells were collected
by trypsinization followed by centrifugation (3500rpm for
5min). Cell pellets were washed twice with PBS and then
resuspended in 1X binding buﬀer for a ﬁnal concentration
of 1 × 106 cells/mL. Cells were treated with Annexin V-FITC
and PI using the Apoptosis Detection Kit (BD Bioscience
Pharmingen, San Jose, CA) according to the manufacturer’s
protocol. The reactions were subsequently quenched by the
addition of 150μL 1X binding buﬀe r .D a t aw e r ec o l l e c t e d
using a BD FACSCalibur, and quadrant analysis of co-
ordinate dot blots was performed using FlowJo 8.4.6. Data
represent two independent experiments run in duplicate.
2.7. EGF-Induced Autophosphorylation Assay. U87MG cells
were plated in 6-well plates using serum-supplemented
medium and allowed to attach overnight. At 85–90%
conﬂuency, the wells were rinsed with PBS and the cells
were starved for 24h. Treatments consisted of 2h exposures
to the drugs followed by a quick rinse with PBS and a
further 20min treatment with 50ng/mL EGF. Treatments
were terminated by rinsing the wells with ice cold PBS and
placing the plates on ice. Cells were scraped using a rubber
policeman, and cell suspensions were transferred to labelled
eppendorf tubes. Samples were centrifuged for two minutes
at 10 000rpm at 4◦C, and the supernatant was removed. Cell
pellets were homogenized in ice-cold lysis buﬀer (50mM
Tris-HCl pH 7.5, 150nM NaCl, 1% NP-40, 1mM EDTA,
5mM N aF , 1mM N a 3VO4, 1 complete protease inhibitor
tablet Roche Biochemicals, Laval, QC) and incubated for
3 0m i no ni c e .S a m p l e sw e r ec e n t r i f u g e da t1 00 0 0r p mf o r
20min at 4◦C to remove cellular debris. Protein concen-
trations of the supernatants were determined by Bradford
assay using known dilutions of BSA as standards. Samples
(40μg) were solubilized in Laemmli sample buﬀer, placed in
boiling water for 5min and fractionated by electrophoresis
on a 10% SDS-polyacrylamide gel. The fractionated proteins
were transferred by electrophoresis to 0.2μm polyvinyli-
dene diﬂuoride (PVDF) membranes (Millipore, Bedford,6 Journal of Signal Transduction
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Figure 3: Dose-dependent inhibition of EGF-induced Erk 1/2
activation in U87MG (a), U87/EGFR (b) and U87/EGFRvIII (c)
glioma cells. Serum-starved cells were treated with the indicated
concentrations of Iressa ± mechlorethamine (HN2), ZRBA4 or
ZR2003 for 2h followed by a 20min EGF (50ng/mL) stimulation.
Cell lysates (40μg) were fractionated by SDS-PAGE and probed
with anti-phospho-Erk 1/2 (1:1000) antibodies (see Materials
and Methods for details). Blots were subsequently stripped and
reprobed for total Erk 1/2 (1:1000) followed by α-actinin (1:1500).
Major protein bands of 44, 42 (Erk 1/2) and 100 kDa (α-actinin)
were obtained.
MA). Membranes were blocked, incubated with primary
antibodies and then HRP-conjugated secondary antibodies
(1:25000 in 0.1% TBST) followed by chemiluminescence
detection with the ECL Advance Western Blotting Detection
kit (Amersham Biosciences) in accordance with the man-
ufacturer’s instructions. Molecular weights were estimated
using the BenchMark prestained Western Protein Standard
(Invitrogen). Images were captured using an Alpha Innotech
FluorChem 8800 gel box imager, and densitometry was
carried out using FluorChem software (Alpha Innotech
Co.). Percent changes in ErbB1 tyrosine phosphorylation
expression were calculated as the ratio between the density
of the phosphorylated tyrosine band (185kDa) and the band
density for EGFR. These values were subsequently corrected
for loading (using α-actinin) and then for basal expression
(control level was set at 1).
2.8. Western Blot Analysis. To investigate Erk 1/2 and Akt
inhibition, U87 glioma cells were cultured and treated as
described for the EGF-induced autophosphorylation assay.
All other Western Blot analyses were executed on cells that
were grown and treated in serum-supplemented medium for
48h. Protein extraction and quantiﬁcation were performed
as described in the EGF-induced autophosphorylation assay.
Samples (40 or 100μg) were solubilized in Laemmli sample
buﬀer, boiled, and fractionated by electrophoresis on 10, 12,
or 15% SDS-polyacrylamide gels. The fractionated proteins
were transferred to PVDF membranes. The membranes were
subsequently blocked, incubated with primary antibody and
then with HRP-conjugated secondary antibody (1:25 000
dilution in 0.1% TBST). Signals were detected with the ECL
Advance Western Blotting Detection kit in accordance with
the manufacturer’s instructions. Molecular weights were
estimated using the BenchMark prestained Western Protein
Standard. Images were captured using an Alpha Innotech
FluorChem 8800 gel box imager, and densitometry was
carried out using FluorChem software. Percent changes in
protein activation (p-Erk 1/2, p-Akt, p-Bad) were calculated
as the ratio between the density of the phosphorylated band
and the band density for total Erk 1/2, Akt, or Bad, respec-
tively. These values were subsequently corrected for loading
(using α-actinin) and then for basal expression (control level
was set at 1). Expression levels of all other proteins were
calculated as the ratio between the density of the band of
interest and the band density for the loading control (i.e., α-
actinin). These values were subsequently corrected for basal
expression (control level was set as 1).
3. Results
3.1. Inhibition of ErbB1-Mediated Signalling. Recent studies
havereportedstrongErbB1TKinhibitoryactivityforZRBA4
(4.4nM) and ZR2003 (26nM) [23, 24]. Therefore, we
ﬁrst investigated their ability to inhibit ErbB1 activation
in our isogenic panel of brain tumour cells. All ErbB1
TKIs (Iressa, ZRBA4 and ZR2003) attenuated EGF-induced
ErbB1 tyrosine phosphorylation in U87MG as well as
U87/EGFRvIII cells (Figure 2). Moreover, Iressa and ZR2003
slightly decreased EGFRvIII phosphorylation. Similarly, at
the concentrations tested, only Iressa and ZR2003 blocked
ErbB1 phosphorylation in U87/EGFR cells.
We next determined whether inhibition of ErbB1 phos-
phorylation translated into attenuation of the downstream
MAPK pathway, through which EGF induces proliferation
(Figure 3). Iressa and ZR2003 inhibited Erk 1/2 phosphory-
lation in U87MG cells, while only Iressa attenuated Erk 1/2
activation in U87/EGFR cells. While ErbB1 phosphorylation
in the U87/EGFRvIII cell line was inhibited by all TKIs or
combi-molecules, they only induced moderate inhibition of
EGFRvIII phosphorylation. Therefore, we had in hand all
the levels of eﬀects needed to examine cell response to the
divergent targeting approach. When the combi-molecules
or combination of Iressa + HN2 were coadministered with
the SSTR agonist octreotide (OCT), no signiﬁcant change
in Erk1/2 phosphorylation status of the cells was observedJournal of Signal Transduction 7
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Figure 4: Representative histograms illustrating Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, and ZR2003-induced cell cycle
arrest in U87MG (a), U87/EGFR (b), and U87/EGFRvIII (c) glioma cells following a 48h treatment. Cell cycle perturbations following
concomitant treatment with 1μM octreotide (OCT) are shown in the lower panels. ∗Shows statistical diﬀerences, within the same phase of
the cell cycle, between drug alone and drug + OCT (P<0.05).8 Journal of Signal Transduction
Table 1: Relative distribution of U87MG, U87/EGFR, and U87/EGFRvIII glioma cells across the G1, S, and G2 phases of the cell cycle. Cells
were treated for 48h with Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, and ZR2003 in the absence or presence of 1μM octreotide
(OCT).
U87MG U87/EGFR U87/EGFRvIII
Control
G1 73.0 ± 3.48 0 .0 ± 2.28 3 .3 ±0.2
S1 0 .2 ±1.54 .2 ±2.17 .6 ±0.6
G2 17.3 ±1.61 5 .7 ± 0.19 .1 ±0.3
1μMO C T
G1 77.2 ±0.88 2 .7 ± 2.98 2 .7 ±1.2
S9 .3 ±0.35 .9 ±3.07 .0 ± 1.1
G2 18.0 ±2.61 1 .5 ± 0.11 0 .3 ± 0.7
12.5μMH N 2
G1 51.5 ±7.82 0 .7 ± 2.75 5 .0 ±0.2
S3 6 .1 ±1.74 9 .1 ± 8.62 4 .8 ±1.8
G2 20.1 ±0.74 5 .5 ± 0.92 0 .1 ±1.7
12.5μMH N 2+1μMO C T
G1 18.7 ±2.2
∗ 30.6 ± 3.81 9 .6 ±4.7
∗
S4 8 .7 ±7.52 8 .9 ± 2.77 1 .7 ±2.2
∗
G2 59.5 ±2.3
∗ 35.0 ± 2.44 1 .8 ±1.8
∗
12.5μM Iressa
G1 49.6 ±5.76 3 .6 ± 0.45 8 .2 ±2.3
S1 8 .6 ± 1.21 5 .3 ± 2.31 5 .7 ± 0.5
G2 21.9 ± 1.02 2 .1 ± 2.92 2 .5 ± 1.2
12.5μMI r e s s a+1μMO C T
G1 53.1 ± 4.75 8 .3 ± 2.56 6 .3 ± 2.8
S4 0 .5 ± 2.6
∗ 22.7 ±2.12 4 .7 ± 2.3
∗
G2 16.6 ±1.7
∗ 16.0 ± 1.71 3 .6 ±1.4
12.5μM( I r e s s a+H N 2 )
G1 25.7 ±6.43 2 .0 ± 3.43 2 .5 ±9.3
S1 9 .7 ±1.83 2 .0 ± 5.92 3 .5 ±9.5
G2 39.6 ±17.43 3 .6 ± 1.84 4 .7 ±0.3
12.5μM( I r e s s a+H N 2 )+1μMO C T
G1 23.5 ±3.93 9 .5 ± 3.83 4 .9 ±3.9
S5 1 .9 ±10.11 8 .9 ± 2.41 7 .2 ±5.3
G2 19.0 ±2.92 2 .3 ± 2.25 2 .1 ±1.2
∗
12.5μMZ R B A 4
G1 12.2 ±0.31 5 .6 ± 0.26 0 .5 ±0.3
S5 6 .1 ±1.37 1 .4 ± 1.81 2 .9 ±0.3
G2 31.1 ±0.83 3 .5 ± 2.52 6 .5 ±0.1
12.5μMZ R B A 4+1μMO C T
G1 20.3 ±6.93 1 .4 ± 2.32 2 .9 ±4.7
S5 9 .3 ±4.03 9 .0 ± 4.1
∗ 50.6 ±3.2
∗
G2 23.7 ±3.42 8 .8 ± 2.12 8 .3 ±0.8
12.5μM ZR2003
G1 52.1 ±4.62 8 .3 ±1.93 5 .3 ±1.5
S 26.3 ± 2.3 54.3 ±2.75 3 .5 ±0.9
G2 15.7 ± 2.0 12.7 ± 0.21 3 .9 ±1.7
12.5μM ZR2003 + 1μMO C T
G1 49.5 ± 4.63 2 .6 ± 3.62 8 .7 ±1.9
S2 5 .7 ± 1.65 7 .8 ± 0.95 7 .1 ±0.5
G2 19.3 ± 1.51 2 .5 ± 1.31 2 .1 ±2.6
∗Shows statistical diﬀerences, within the same phase of the cell cycle, between drug alone and drug + OCT (P < 0.05).
(data not shown). Total Erk 1/2 was relatively even across all
treatments in U87 and U87/EGFR cell lines, while a dose-
dependent increase was observed in U87/EGFRvIII calls, an
eﬀect that may be speciﬁc to the latter cell type.
3.2. Cell Cycle Analysis
3.2.1. HN2 + Iressa ± OCT-Induced Cell Cycle Perturbations.
HN2 is a bifunctional alkylating agent that induces high
levels of DNA cross-links. It is known to induce cell cycle
arrest at all phases of the cell cycle. At high concentrations,
it blocks cells in G1 and at low concentrations, it induces
cell cycle arrest in S and G2/M. On the other hand, Iressa
is known to arrest cells in G1. As demonstrated in Figure 4
and Table 1, treatment with 12.5μMo fH N 2i n d u c e dc e l l
cycle arrest in S in U87MG and U87/EGFRvIII transfectant
cells but strong S (late) and G2/M arrest in the U87/EGFR
cells. Surprisingly, Iressa induced some cell cycle arrest inJournal of Signal Transduction 9
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Figure 5: Dose-dependent changes in p53 phosphorylation (Ser15)
and expression in U87MG (a), U87/EGFR (b), and U87/EGFRvIII
(c) glioma cells treated for 48h. Cell lysates (40μg) were fraction-
ated by SDS-PAGE and probed with antiphospho-p53 (1:1000)
antibodies (see Materials and Methods for details). Blots were
subsequentlystrippedandreprobedfortotalp53(1:1000)followed
by α-actinin (1:1500). Major protein bands of 53 (p53) and 100
kDa (α-actinin) were obtained.
the S phase. When the two drugs (HN2 and Iressa) were
combined, a dramatic change in cell cycle distribution was
induced leading to increased S (late) and G2/M arrest in all
three cell types. More importantly, addition of OCT shifted
the cell cycle arrests to S.
3.2.2. ZRBA4 ± OCT-Induced Cell Cycle Perturbations.
ZRBA4 is designed to be a prodrug of a DNA cross-linking
alkylating species similar to HN2 and an ErbB1 TKI. It
is therefore a unimolecular mimic of the HN2 + Iressa
combination. ZRBA4 induced cell cycle arrest in S and G2M
in U87MG and U87/EGFR cells (Figure 4, Table 1). Addition
of OCT further perturbed cell cycle distribution proﬁles in
a cell-dependent manner. U87MG cells shifted from S and
G2/M arrest to the S phase. In contrast, OCT enhanced the
accumulation of U87/EGFR cells in G1 at the expense of
the S phase while leaving the G2/M population unchanged.
Meanwhile, U87/EGFRvIII cells accumulated in the G2/M
phase of the cell cycle in the absence of OCT. However,
addition of OCT dramatically changed the cell cycle proﬁle,
leading to strong cell cycle arrest in late S and G2M.
3.2.3. ZR2003 ± OCT-Induced Cell Cycle Perturbations.
ZR2003 is a combi-molecule that does not require metabolic
activationtogenerateitsDNAdamagingspecies:itcaneither
block ErbB1 tyrosine kinase activity or damage DNA, and,
unlike ZRBA4 and HN2, it cannot generate DNA cross-links.
Therefore, its mechanism of action is diﬀerent from that of
ZRBA4. Interestingly, while ZR2003 induced S phase arrest
in all three isogenic cell lines (Figure 4, Table 1), its eﬀect
was not altered by OCT, indicating the eﬀects of OCT may
be dependent on the type of DNA lesions induced by these
drugs.
3.3. p53 Expression and Ser15 Phosphorylation. Upon DNA
damage, Ataxia-telangiectasia (ATM), ATM and Rad3-
related (ATR), and DNA-dependent protein kinase (DNA-
PK) activate p53 through phosphorylation at Ser15 [28,
29]. We detected a dose-dependent phosphorylation of p53
at Ser15 in all samples treated with HN2, alone or in
combination with Iressa, and ZRBA4 (Figure 5). Moreover,
treatment with HN2, HN2 + Iressa, and ZRBA4 enhanced
p53 accumulation. Meanwhile, ZR2003, a type II combi-
molecule, elicited the greatest activation as well as accumu-
lation of p53 in all three cell lines. Finally, combination of
OCT with these treatments did not enhance p53 activation
nor expression.
3.4. Alterations of Key Players in the Cell Cycle. To elucidate
the pathway through which SSTR activation could enhance
HN2 ± Iressa and ZRBA4-induced cell cycle arrest, we
investigated changes in p21, a signalling intermediate for
SSTRs as well as other pathways that play a role in cell cycle
arrest. Since OCT enhanced HN2- and ZRBA4-induced S
and G2/M arrest, we investigated whether this eﬀect was
mediated by p21. Unfortunately, p21 was not detectable
in these cells, potentially due to downregulation by Akt.
Based on these results, we decided to verify the expression
of GADD45, another signalling intermediate in p53-induced
G2/M arrest. The results showed that GADD45 was activated
wherever p53 was phosphorylated (data not shown).
3.5. Eﬀect of ErbB1 Inhibition on DNA Repair Proteins.
Eukaryotes have developed multiple types of DNA repair
systems to ensure genomic ﬁdelity before replication. ATM,
ATR, and DNA-PK kinases check genomic integrity at the
G1/S and G2/M checkpoints. Moreover, stimulation of
ErbB1 has been reported to induce DNA repair proteins such
as ERCC1 and XRCC1 [30] .T h ef o r m e rp l a y sar o l ei n
nucleotide excision repair (NER) and recombination repair,
while the latter is involved in base excision repair (BER)
and nonhomologous end-joining (NHEJ). HN2, as a bifunc-
tional alkylator, damages DNA by alkylating its bases mainly
at the N7 position of guanine [31–33]. This can result in
DNA base pair mismatches as well as intra- and interstrand
crosslinks. The N7-alkyl guanine can be repaired by BER,
while the crosslinks are generally repaired by homologous
recombination repair (HRR) and NHEJ. ERCC1 was upreg-
ulated in all three cell lines following a 48h exposure to
Iressa + HN2, ZRBA4, or ZR2003 (Figure 6). ZR200310 Journal of Signal Transduction
−
−
−
−
−
−
−
−
−
−
−
−
α-actinin
ERCC1
C
o
n
t
r
o
l
1
0
n
M
 
E
G
F
1
μ
M
 
O
C
T
1
0
n
M
 
E
G
F
+
1
μ
M
 
O
C
T
1
2
.
5
μ
M
 
I
r
e
s
s
a
1
2
.
5
μ
M
 
I
r
e
s
s
a
2
5
μ
M
 
I
r
e
s
s
a
2
5
μ
M
 
I
r
e
s
s
a
1
2
.
5
μ
M
 
Z
R
B
A
4
2
5
μ
M
 
Z
R
B
A
4
1
2
.
5
μ
M
 
Z
R
B
A
4
2
5
μ
M
 
Z
R
B
A
4
++ ++ ++ ++ ++ ++
2
5
μ
M
 
I
r
e
s
s
a
+
H
N
2
1
2
.
5
μ
M
 
I
r
e
s
s
a
+
H
N
2
1
2
.
5
μ
M
 
I
r
e
s
s
a
+
H
N
2
2
5
μ
M
 
I
r
e
s
s
a
+
H
N
2
2
5
μ
M
 
H
N
2
1
2
.
5
μ
M
 
H
N
2
1
2
.
5
μ
M
 
H
N
2
2
5
μ
M
 
H
N
2
1
2
.
5
μ
M
 
Z
R
2
0
0
3
1
2
.
5
μ
M
 
Z
R
2
0
0
3
2
5
μ
M
 
Z
R
2
0
0
3
2
5
μ
M
 
Z
R
2
0
0
3
OCT
(a)
α-actinin
ERCC1
(b)
α-actinin
ERCC1
(c)
Figure 6: Upregulation of ERCC1 expression in U87MG (a), U87/EGFR (b), and U87/EGFRvIII (c) glioma cells. Cells were treated with
the indicated concentrations of Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, or ZR2003, alone or in combination with octreotide
(OCT) for 48h. Cell lysates (40μg) were fractionated by SDS-PAGE and probed with anti-ERCC1 (1:1000) antibodies (see Materials and
Methods for details). Blots were subsequently stripped and reprobed for α-actinin (1:1500). Major protein bands of 36 (ERCC1) and
100kDa (α-actinin) were obtained.
Table 2:InhibitionofU87MG,U87/EGFR,andU87/EGFRvIIIcellgrowthbyIressa ±mechlorethamine(HN2),ZRBA4,andZR2003,alone
or in combination with 1μM octreotide (OCT), as assessed by the alamar blue assay.
U87 U87/EGFR U87/EGFRvIII
IC50 (μM) IC50 (μM) IC50 (μM)
OCT n/a n/a n/a
Iressa 11.89 ±8.40 2.96 ±0.05 34.14 ±3.53
Iressa + OCT 13.01 ±9.70 3.27 ±0.28 32.23 ±3.80
HN2 9.58 ±1.20 1.52 ±0.59 19.74 ±2.85
HN2 + OCT n/a 1.81 ±0.68 13.33 ±3.78
Iressa + HN2 14.51 ±0.20 0.77 ±0.27 15.82 ±1.97
Iressa + HN2 + OCT 12.24 ±1.53 0.66 ± 0.13 n/a
ZRBA4 8.27 ±0.57 3.91 ±0.62 7.50 ±0.82
ZRBA4 + OCT 8.20 ±0.59 3.58 ±0.52 7.45 ±0.62
ZR2003 0.82 ±0.24 0.87 ±0.14 0.54 ±0.18
ZR2003 + OCT 0.77 ±0.19 0.73 ±0.08 0.43 ±0.14
Values are presented as mean ± SEM and are representative of 3 experiments run in triplicate.
elicited the strongest response in U87MG cells, while ERCC1
expression in U87/EGFR cells was most strongly upregu-
lated in response to ZRBA4. Moreover, U87/EGFRvIII cells
showed the strongest upregulation of ERCC1 with Iressa
+ HN2, ZRBA4, and ZR2003 eliciting similar degrees of
upregulation. In contrast, XRCC1 was not detected over the
course of the 48h treatments (data not shown).
3.6. Antiproliferative Activity of ZRBA4, ZR2003, Iressa, HN2,
and OCT. We next investigated the anti-proliferative eﬀects
of ZRBA4, ZR2003, Iressa, and HN2, alone as well as in com-
binationwithOCT,usinga6-dayalamarblueassay(Table 2).
ZRBA4, a type I combi-molecule, demonstrated 1.4-and-4.5
fold superior antiproliferative activity (P<0.05) over Iressa
in U87MG and U87/EGFRvIII cells, respectively. ZRBA4 also
slightly enhanced growth inhibition over HN2 in U87MG
cells,whileitinduceda2.6-foldincreaseincellkillcompared
withHN2inU87/EGFRvIIIcells.Consistentwiththecombi-
targeting concept, a 6-day treatment with ZRBA4 resulted
in a 1.8-to 2.1-fold superior inhibition of proliferation (P<
0.05) compared with the two-drug Iressa + HN2 combina-
tion in U87MG and U87/EGFRvIII cells (Figure 7, Table 2).
In addition, ZRBA4 showed 2.1-fold selectivity for ErbB1-
overexpressing cells (P<0.05); however, in U87/EGFR cells,Journal of Signal Transduction 11
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Figure 7: Relative growth inhibition of ZRBA4, ZR2003, and equimolar combination of Iressa + mechlorethamine (HN2) in U87MG (a),
U87/EGFR (b), and U87/EGFRvIII (c) isogenic glioma cells. Cells were exposed to each drug for 6 days, and growth inhibition was measured
by alamar blue assay (see Materials and Methods for details). Each point represents three independent experiments run in triplicate.
it was less eﬀective at inhibiting proliferation than Iressa,
HN2, and Iressa + HN2. In contrast, ZR2003, a type II
combi-molecule, demonstrated a slight selectivity (1.5-fold)
fortheEGFRvIIImutation.Itshowed14.5-,3.4-,and63-fold
superior antiproliferative activity (P<0.05) over Iressa in
U87MG, U87/EGFR, and U87/EGFRvIII cells, respectively.
Moreover, in U87/EGFRvIII cells, ZR2003 demonstrated a
statistically signiﬁcant (P<0.05) 29.3-fold enhancement
of cell kill over Iressa + HN2 (Figure 7) .Am o r em o d e r a t e
11.7-and 17.7-fold increase in growth inhibition (P<
0.05) was detected in U87MG cells treated with HN2 or
Iressa + HN2, respectively. We also investigated whether
simultaneous activation of SSTRs with OCT would enhance
the antiproliferative activity of the binary-targeted combi-
molecules but did not detect any signiﬁcant interactions.
3.7. Apoptosis. We subsequently determined how the
observed cell cycle perturbations would translate into
apoptosis (Figures 8 and 9). Cell death was induced in
the three cell lines by HN2 as well as Iressa + HN2.
Interestingly, a shorter (24h) treatment with HN2 mainly
induced a nonapoptotic cell death pathway, while we
detected some cells undergoing apoptosis following a longer
(48h) exposure (Figure 8). Meanwhile, ZRBA4 induced
minimal cell death in U87/EGFRvIII (data not shown) and
U87MG cells and nonapoptotic cell death in U87/EGFR
cells (Figure 8). Moreover, ZR2003 showed dose-dependent
induction of cell death with relatively strong early (within
24h) induction of nonapoptotic cell death (Figure 8).
Finally, when we combined 1μM OCT with the above
treatments, we did not detect any potentiation of cell death.12 Journal of Signal Transduction
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Figure 8: Representative Annexin V/propidium iodide (PI) intensity dot blots of U87MG (a) and U87/EGFR (b) cells treated for 24 (upper
panels) or 48h (lower panels) with Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, or ZR2003. Cell death was determined by
Annexin V and propidium iodide (PI) staining (see Materials and Methods for details). Data are the mean of two independent experiments
run in duplicate.
3.8. Modulation of Apoptotic as well as Antiapoptotic Sig-
nalling. To rationalize the lack of apoptosis, we extended
our investigation to the analysis of key components of the
DNA damage response pathway and the intrinsic apoptotic
pathway. Based upon reports that DNA alkylators, including
HN2, induce apoptosis partially through JNK activation, we
investigated JNK and p38 activation by Western Blot analysis
[34, 35]. Neither JNK nor p38 activation were detected (data
not shown). This is consistent with the lack of induced
apoptosis.
ThePI3K/Aktpathway,anothermajordownstreameﬀec-
tor pathway of ErbB1, promotes cell survival by inhibiting
apoptosis as well as modulating cell cycle arrest. We,
therefore, veriﬁed whether the combi-molecules could alter
Akt phosphorylation. However, due to a PTEN mutation in
these cells, Akt was constitutively phosphorylated at Ser473
and unresponsive to ErbB1 inhibition (data not shown).
Since these cells responded to DNA damage with p53
activation as well as upregulation, we further extended
our investigation and veriﬁed Bad phosphorylation at both
Ser112 and Ser136. Phosphorylation of these two sites (by
MEK1 and Akt, respectively) plays a critical role in cell
survival through sequestration of Bad with 14-3-3 proteins
thereby preventing Bad from binding Bcl-2 or Bcl-xL and
subsequently releasing proapoptotic Bax. Therefore, we
determined the extent to which our drugs modulated Bad
phosphorylation. We also investigated whether combining
OCT with the above treatments would further alter Bad
phosphorylation. Bad was constitutively phosphorylated at
Ser112 and Ser136 in U87 and U87/EGFRvIII cells (data
not shown). In contrast, total Bad was barely detectable in
U87/EGFRcells(datanotshown).NotreatmentreducedBad
phosphorylation at either site. Moreover, OCT had no eﬀect
on Bad phosphorylation (data not shown).Journal of Signal Transduction 13
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Figure 9: Assessment of apoptotic eﬀects induced by Iressa ± mechlorethamine (HN2), ZRBA4, and ZR2003. U87MG (a) and U87/EGFR
(b) cells were treated for 24 (i) or 48h (ii). Levels of cell death were determined by Annexin V and propidium iodide (PI) staining. Bars for
apoptotic cell death represent the mean percentage of Annexin-V-positive cells. Total cell death encompasses early and late apoptotic as well
as necrotic cell death. Data are the mean of two independent experiments run in duplicate. ∗Statistically diﬀerent from control (P<0.05).
SSTR3 has been shown to play a role in p53-mediated
apoptosis, while the other four SSTRs induce cell cycle
arrest via p21 or p27. With no clear enhancement of p53,
Bad, p21, or GADD45 by OCT, we extended our study to
include another key protein in apoptosis, survivin. Survivin,
an inhibitor of apoptosis protein (IAP), is most recognized
for its role in chromosome segregation and cytokinesis
[36, 37]. In addition to its role in cell division, survivin
overexpression is associated with inhibition of apoptosis via
both the extrinsic as well as intrinsic pathways although it
is more efﬁcient at blocking the latter pathway [38, 39]. In
general, survivin and p53 negatively regulate each other’s
expression. However, as illustrated in Figure 10,Z R B A 4
enhanced survivin as well as p53 (Figure 5) expression
conﬁrming blockage of apoptosis. In contrast, in HN2-
and ZR2003-treated gliomas cells, p53 and survivin were
inversely related (Figures 5 and 10) while Iressa attenuated
the HN2-mediated inhibition of survivin. We did not detect
anyOCT-inducedregulationofsurvivinexpression(datanot
shown).
4. Discussion
The eﬀectiveness of single-targeted cancer therapies is mit-
igated by the inevitable onset of drug resistance. This may
arise due to alternate pathways compensating for the drug
target or to the accumulation of mutations within the target
or components of downstream signalling pathways. There-
fore, classical cancer therapies generally combine multiple
drugs with diﬀerent mechanisms of action to prevent drug14 Journal of Signal Transduction
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Figure 10: Treatment-dependent regulation of survivin expression in U87MG (a), U87/EGFR (b), and U87/EGFRvIII (c) glioma cells. Cells
were treated with the indicated concentrations of Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4 or ZR2003 for 48h. Cell lysates
(40μg)werefractionatedbySDS-PAGEandprobedwithantisurvivin(1:2000)antibodies(seeMaterialsandmethodsfordetails).Blotswere
subsequently stripped and reprobed for α-actinin (1:1500). Major protein bands of 16 (survivin) and 100kDa (α-actinin) were obtained.
resistance. However, due to the nonspeciﬁc nature of their
binding, some combinations can result in increased toxicity.
Moreover, the potency of these drugs is often mitigated by
DNA repair pathways. Therefore, novel chemotherapeutic
approaches are urgently needed. In this study, we exam-
ined our divergent targeting strategy using DNA damage,
ErbB1 TK inhibition, and SSTR activation. We used OCT
as our SSTR agonist, while HN2 + Iressa, ZRBA4 and
ZR2003, chloroethylating combi-molecules, induced con-
current DNA damage and ErbB1 inhibition.
Previous studies have demonstrated the binary ErbB1-
D N At a r g e t i n gp r o p e r t i e so fZ R B A 4a sw e l la si t sa b i l i t y
to induce DNA interstrand crosslinks in a manner similar
to that of HN2 [23]. Consistent with literature, ZRBA4, as
a partially irreversible ErbB1 inhibitor, showed selectivity
for ErbB1-overexpressing cells. Furthermore, it manifested
characteristics of both components (DNA damage and
ErbB1 inhibition) as outlined by the similarity of the cell
cycle perturbation proﬁle that it induced when compared
with equivalent two-drug combinations of HN2 + Iressa.
Likewise, cell cycle arrest induced by the two forms of
combinations (i.e., individual drugs or unimolecular combi-
molecules) was signiﬁcantly enhanced by OCT activation
of SSTRs in these cells. Notably, OCT altered the cell cycle
distribution proﬁle of cells exposed to the DNA damaging
agent HN2 more dramatically than those treated with
the ErbB1 inhibitor Iressa. However, its eﬀect was more
dramaticwhenHN2wascombinedwiththeErbB1inhibitor,
suggestingthatErbB1inhibitionplaysaroleintheoverallcell
cycle perturbation. As outlined in Scheme 2, SSTR activation
induces cell cycle inhibitors, while ErbB1 phosphorylation
downregulates them. Thus, inhibition of ErbB1 that leads
to downregulation of downstream signalling (e.g., Erk1/2
activation) may relieve any antagonistic eﬀect to SSTR-
mediated cell cycle arrest.
In general, SSTR1, 2, 4, and 5 induce G1 arrest in a
p53-independent manner while SSTR3 induces apoptosis
through a p53/Bax-dependent mechanism [40–43]. Previous
studies have shown that SSTR3-mediated p53 activation
occurs independently of cell cycle arrest and p21 induction
[44]. Moreover, p53-mediated activation of p21 promotes
G1 arrest while loss of G1/S checkpoint control generally
sensitizes cells to DNA damage. We did not detect p21 in
our samples nor did the nitrogen mustard-containing com-
pounds (HN2, ZRBA4, and ZR2003) induce signiﬁcant G1
arrest, suggesting that the p53 activation and upregulation
observed in the Western Blot analyses may not be related
to cell cycle arrest. Thus the increased eﬀect conferred by
OCT may be due to a direct eﬀect of SSTR activation on the
cell cycle through induction of cell cycle inhibitors or otherJournal of Signal Transduction 15
proteins that trigger the cells to arrest earlier in the cycle
in response to the DNA damage induced by HN2 and our
combi-molecules.
While p53 is generally associated with the induction of
apoptosis, the absence of Bax upregulation and Bad dephos-
phorylation demonstrates that the p53-mediated apoptotic
pathway is blocked. Moreover, the increased expression of
survivin, an inhibitor of apoptosis protein (IAP), provides
further evidence that the drugs tested in this study cannot
induce apoptosis. However, HN2 (but not Iressa + HN2)
activated and upregulated p53 as well as downregulated
survivin expression after a 48h treatment which translated
into cells dying by both apoptosis (ca. 50%) and a nonapop-
totic form of cell death. In contrast, ZR2003 showed the
strongest p53 activation of all the drugs and combinations
of drugs tested in this study. Yet, the concomitant decrease
in survivin levels did not translate into increased apoptosis
suggesting that the observed decline was not due to drug-
induced inhibition, as observed with HN2, but was perhaps
due to rapid turnover (t1/2 = 30min) of the protein in the
G1 phase of the cell cycle [45]. In toto, these data suggest that
the concomitant inhibition of survivin may allow these cells
to undergo apoptosis.
5. Conclusions
In summary, the results presented herein demonstrate that
ErbB1 TKIs inhibit ErbB1 but not EGFRvIII phosphoryla-
tion. Moreover, due to a PTEN mutation, Akt was constitu-
tively active and Bad remained phosphorylated, preventing
cellsfromundergoingapoptosisuponErbB1inhibition.This
may have played a role in p21 downregulation which could
explain the absence of OCT-induced cell cycle arrest on its
own. However, OCT potentiated arrest in the S-phase of the
cell cycle when combined with Iressa ± HN2, or ZRBA4.
Moreover, both Bax unresponsiveness to p53 activation and
survivin upregulation despite p53 activation may contribute
to the cells dying via a nonapoptotic pathway. Thus, future
studies to improve the divergent targeting strategy should
be directed at bridging the strong cell cycle perturbation
observed to a cell death pathway.
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